Hakala Medical develops a product that chemically loosens internal surgical adhesions, removing the need for manual scar dissection. This technology mitigates the significant risk of accidental organ injury during reoperations, which currently costs the US healthcare system billions annually. The solution aims to improve surgical outcomes by enabling safer, chemically assisted adhesiolysis.
Funding
Funding not disclosed
Founders
Product
Problem
During reoperations, surgeons must dissect internal surgical scars to access the target site, a process that carries a 20% risk of accidental organ perforation. These iatrogenic injuries contribute to significant additional surgical costs and negatively impact patient recovery.
Solution
Hakala Medical is developing a chemical solution designed to safely loosen internal surgical adhesions, thereby mitigating the risk of accidental organ damage during subsequent surgical procedures. This approach aims to replace the current manual dissection method, which utilizes sharp instruments and carries a substantial risk of iatrogenic injury. By chemically facilitating adhesiolysis, the technology seeks to enhance surgical safety and efficiency, leading to improved patient outcomes and reduced healthcare expenditures. The solution is intended to be applied intraoperatively by surgeons.
Target Audience
The primary target audience includes general surgeons, minimally invasive surgeons, and hospital systems focused on improving surgical safety and reducing operative complications.
Features
- Chemical agent formulated for safe and effective loosening of internal surgical adhesions.
- Designed to reduce the incidence of iatrogenic injuries during reoperative surgery.
- Potential to decrease direct surgical costs associated with managing accidental organ perforations.
- Aims to improve patient recovery trajectories by minimizing surgical trauma.